missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ EGFR (L858R Mutant) Recombinant Rabbit Monoclonal Antibody (RM380)

Rabbit Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA544561
This item is not returnable.
View return policy
Description
EGFR (L858R Mutant) Recombinant Monoclonal Antibody for Western Blot, ICC/IF, IHC (P)
EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.
Specifications
| EGFR (L858R Mutant) | |
| Recombinant Monoclonal | |
| 100 μg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.09% sodium azide | |
| P00533 | |
| EGFR | |
| A peptide corresponding to human EGFR (L858R Mutant Specific). The immunogen range is a synthetic peptide within to amino acids 800-900 of EGFR with L858R mutant. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| RM380 | |
| Unconjugated | |
| EGFR | |
| EGFR; Erbb1 | |
| Rabbit | |
| Protein A | |
| RUO | |
| 1956 | |
| -20°C | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction